脑动静脉畸形单次立体定向放射外科体积限制再评估:剂量-体积关系深入分析
该回顾性研究分析610例接受单次SRS的脑AVM患者,按体积分四组,比较常规剂量(18-22 Gy)与低剂量(<18 Gy)的疗效。结果显示常规剂量组大体积AVM的闭塞率更优、症状性神经事件和出血率更低,提示采用消融剂量时单次SRS可考虑用于约20 mL以下的AVM。
要点
- 常规消融剂量下,大体积AVM的6年闭塞率可达79%。
- 大体积AVM低剂量SRS的5年SNE率和8年出血率显著更高。
- 单次SRS在消融剂量下或可接受至约20 mL的AVM。
核心结论
- 采用消融剂量时,大体积AVM的单次SRS结局总体良好。
- 若使用消融剂量,单次SRS可考虑用于体积达约20 mL的AVM。
研究设计与样本
- 回顾性分析610例连续接受单次SRS的脑AVM患者,处方剂量为常规18-22 Gy或低剂量<18 Gy。
- AVM按体积分为四组:小<5 mL、中≥5且<10 mL、中大型≥10且<15 mL、大≥15 mL。
- 常规剂量组最大体积22.5 mL,低剂量组最大体积23.5 mL。
主要发现
- 常规剂量组四组AVM的6年累积闭塞率分别为86%、80%、87%、79%。
- 常规剂量组四组AVM的10年累积症状性神经事件(SNE)率分别为2.6%、3.9%、6.8%、5.3%。
- 大体积AVM中,常规剂量组6年累积闭塞率为79% vs 低剂量组48%(P = .111)。
- 大体积AVM中,常规剂量组5年累积SNE率为5% vs 低剂量组31%(P = .038)。
- 大体积AVM中,常规剂量组8年累积SRS后出血率为0% vs 低剂量组54%(P = .002)。
关键数值与推荐
- 多因素分析显示常规剂量SRS显著提高闭塞率并降低SNE和出血。
- 常规剂量定义为18-22 Gy,低剂量定义为<18 Gy。
临床怎么用
- 对大体积AVM(≥10 mL)考虑单次SRS时,应优先采用消融剂量(18-22 Gy)以改善闭塞并降低SNE和出血风险。
- 体积约20 mL以下的AVM在消融剂量下可考虑单次SRS治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-session stereotactic radiosurgery (SRS) for large arteriovenous malformations (AVMs) ≥10 mL remains controversial, which is considered as the current size limitation. OBJECTIVE: To reconsider the size limitation of SRS for AVMs by profoundly analyzing dose-volume relationship. METHODS: Data on 610 consecutive patients with AVM treated with SRS using regular (18-22 Gy) or low (<18 Gy) prescription doses were retrospectively analyzed. AVMs were classified into 4 groups: small (<5 mL), medium (≥5 and <10 mL), medium-large (≥10 and <15 mL), and large (≥15 mL). The maximum volumes were 22.5 mL (regular-dose group) and 23.5 mL (low-dose group). RESULTS: When treated with regular doses, the cumulative 6-yr obliteration rates for each of the 4 AVM groups were 86%, 80%, 87%, and 79%, respectively; the cumulative 10-yr significant neurological event (SNE) rates were 2.6%, 3.9%, 6.8%, and 5.3%, respectively. Regarding large AVMs, regular-dose SRS resulted in marginally better obliteration rate (6-yr cumulative rate, 79% vs 48%, P = .111) and significantly lower SNE (5-yr cumulative rate, 5% vs 31%, P = .038) and post-SRS hemorrhage rate (8-yr cumulative rate, 0% vs 54%, P = .002) compared to low-dose SRS. Multivariate analyses revealed that regular-dose SRS significantly contributed to increase in the obliteration rate and decrease in SNEs and hemorrhage. CONCLUSION: The outcomes for large AVMs were generally favorable when treated with ablative doses. Single-session SRS could be acceptable for AVMs up to ≈20 mL if treated with ablative doses.
引用
- Hasegawa H, Hanakita S, Shin M, et al. Re-Evaluation of the Size Limitation in Single-Session Stereotactic Radiosurgery for Brain Arteriovenous Malformations: Detailed Analyses on the Outcomes with Focusing on Radiosurgical Doses. Neurosurgery. 2020. PMID: 31322166. doi:10.1093/neuros/nyz280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。